General contact

Main switchboard

+41 61 324 11 11
+41 61 324 80 01
Monday - Friday,
8:30 a.m. - 5:00 p.m. GMT+1

US switchboard

+1 862 778 21 00
Monday - Friday,
8:30 a.m. - 5:00 p.m. EST


Global Media Relations
Eric Althoff
Basel, Switzerland

+41 61 324 7999


Investor Relations

Monday - Friday,
8:30 a.m. - 5:30 p.m. GMT+1
(Central European Time)

Reporting side effects

Report a suspected side effect (also known as an adverse event) related to a Novartis Pharmaceutical drug or a Novartis Vaccine.

Reporting side effects

pane 4 content


Preventing diseases with innovative products

As part of a set of interconditional transactions with GlaxoSmithKline Plc (GSK), Novartis divested its Vaccines business (excluding its influenza vaccines business), to GSK on March 2, 2015. In October 2014, Novartis announced that it had reached an agreement with CSL Limited to acquire the Novartis influenza vaccines business. The sale of the influenza vaccines business is expected to close by the end of 2015.

For more information on this transaction, click here.


The Novartis influenza vaccines business is among the world’s largest producers of influenza vaccines. Our products include:

  • Flucelvax

  • Fluvirin

  • Fluad